Last updated: December 6, 2024
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Overall Status: Active - Recruiting
Phase
N/A
Condition
Multiple Myeloma
Lymphoma
Acute Myeloid Leukemia
Treatment
N/AClinical Study ID
NCT04645199
NICHE-cohort
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients who were diagnosed with acute myeloid leukemia, multiple myeloma,hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleedingdisorders or received bone marrow transplantation in the investigating hospitalsfrom January 1, 2020.
Exclusion
Exclusion Criteria:
Long-term follow-up information for patients is not available for any reason, suchas not being available or having a serious concomitant disease.
Alcohol and drug addictions affect their ability to comply with study requirements.
According to the investigator, there are conditions that may endanger the patient'ssafety or affect his/her compliance.
Study Design
Total Participants: 2300
Study Start date:
December 01, 2020
Estimated Completion Date:
December 01, 2030
Connect with a study center
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin 300000
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.